Skip to main content
US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
Screen a stock
TERMINAL
VR

VRTXStock

Nasdaq Global Select Market · Healthcare · US

$516.05 as of 13 hours ago
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment VRTX's does — no target price to set, unlike a price alert.

Near limit Ratio screen, 7 of 7 decided standards passing. AAOIFI, Dow Jones Islamic, FTSE Shariah, MSCI Islamic, MSCI Islamic M-Series, S&P Shariah, Usmani are within 3 points of their line. If they all crossed, the majority verdict would move from Compliant to Not compliant. What would change it

Sharia status
COMPLIANT
Per our in-house ratio engine · assessed 2026-09-30
Assessed 2026-09-30
7 of 7 pass our own screen — all 7 agree here
🕌 Held by HLAL · MNZL HTR non-permissible income 0.02%
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
🟡 BULLISH LEAN
The main driver: outperforming the market by 6.2%, RSI in healthy zone, Wall Street broadly bullish. More signals...
Scores: 3 bullish / 2 bearish
68
of 100
Setup confidence — system conviction, not win probabilityB

Trade plan

Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.

MEAN_REVERSION
Entry
$520.66
Stop
$517.88
Target
$537.93
Risk : Reward 6.2R

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure1 of 5 timeframes bullish · 95.7% aligned
VWAPPrice below VWAP ($530.02)
VolumeRelative volume 2.9× the 20-day average
Momentum10-day rate of change -3.6%
Overall readBULLISH LEAN

VRTX is currently considered halal (Sharia-compliant), per our in-house ratio engine (last assessed 2026-09-30). See the full ratio breakdown and business-activity screen below for the reasoning.

This sits among 437 compliant Healthcare stocks we track. See compliant Healthcare stocks →

Market & analysts
Wall Street consensus
BUY
36 analysts
Institutional own.
98.1%
of shares
Momentum (10d)
-3.6%
rate of change
SMC grade
B · 68
95.7% aligned
🕌 HLAL, MNZL
Held by real halal ETF(s)
0.02%
Non-permissible income — HTR, from filings (2025-12-31)
B · 68
SMC grade — 95.7% timeframe alignment
-3.6%
Rate of change (10d)
BUY
Wall Street consensus (36)
98.1%
Institutional ownership

How the status reached this point

Compliant since Nov 19, 2026

First seen by our daily status check on Nov 19, 2026; it read Not rated on Nov 18, 2026, so the change landed between those two checks.

$536.45 — last close we recorded while it was still Not rated, Nov 18, 2026

  • Nov 19, 2026 Not rated → Compliant7 of 7 decided standards pass; AAOIFI debt ratio 4.6%; figures as of Sep 30, 2026
  • Nov 17, 2026 Tracking began Nothing before this date is on record.

Read once a day from the status this page publishes, last on Nov 20, 2026. The per-methodology record is under “What changed, and when” in the in-house research.

Free email, sent when our compliance re-scan finds a change.

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $141.7B as of 2026-11-19. At the 2026-11-20 close it is about $139.2B (the stored market cap moved by the share price since, not a new share count), and at that cap AAOIFI's interest-bearing debt ratio would read 4.7% (4.6% at the stored cap, against a 30% line) and interest-bearing investments ratio would read 4.5% (4.5% at the stored cap, against a 30% line). The published verdict changes only when the company is re-screened.

Business activity: cleared (no excluded categories detected)

AAOIFI Pass 3 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 4.57% 30.00% Pass(25.4pp buffer)
Interest-bearing investments 4.46% 30.00% Pass(25.5pp buffer)
Non-permissible income 4.09% 5.00% Pass(0.9pp buffer)
Usmani Pass 5 of 5 ratios pass
RatioValueThresholdResult
Interest-bearing debt 19.79% 33.00% Pass(13.2pp buffer)
Interest-bearing investments 19.28% 33.00% Pass(13.7pp buffer)
Non-liquid assets 73.66% at least 20.00% Pass(53.7pp above the floor)
Non-permissible income 4.09% 5.00% Pass(0.9pp buffer)
Net liquid assets per share $3.6B under mkt cap $141.7B Pass
MSCI Pass 4 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 19.79% 33.33% Pass(13.5pp buffer)
Cash + interest-bearing securities 19.28% 33.33% Pass(14.0pp buffer)
Accounts receivable 26.34% 33.33% Pass(7.0pp buffer)
Non-permissible income 4.09% 5.00% Pass(0.9pp buffer)
FTSE Pass 4 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 13.74% 33.33% Pass(19.6pp buffer)
Cash + interest-bearing securities 19.28% 33.33% Pass(14.0pp buffer)
Accounts receivable 26.34% 50.00% Pass(23.7pp buffer)
Non-permissible income 4.09% 5.00% Pass(0.9pp buffer)
Dow Jones Islamic Market Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 5.08% 33.00% Pass(27.9pp buffer)
Cash + interest-bearing securities 4.95% 33.00% Pass(28.1pp buffer)
Accounts receivable 1.81% 33.00% Pass(31.2pp buffer)
Non-permissible income 4.09% 5.00% Pass(0.9pp buffer)
S&P Shariah Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 5.13% 33.00% Pass(27.9pp buffer)
Cash + interest-bearing securities 5.00% 49.00% Pass(44.0pp buffer)
Accounts receivable 1.83% 49.00% Pass(47.2pp buffer)
Non-permissible income 4.09% 5.00% Pass(0.9pp buffer)
MSCI M-Series Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 5.13% 33.33% Pass(28.2pp buffer)
Cash + interest-bearing securities 5.00% 33.33% Pass(28.3pp buffer)
Accounts receivable 6.84% 49.00% Pass(42.2pp buffer)
Non-permissible income 4.09% 5.00% Pass(0.9pp buffer)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

AAOIFI Standard 21 (% of market cap)non permissible income ratio 0.9pts
Usmani (% of total assets)non permissible income ratio 0.9pts
Dow Jones Islamic Market (% of 24-mo avg market cap)non permissible income ratio 0.9pts

The numbers the ratios are built from

Read from VRTX's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $12.0B 2025-12-31 RevenueFromContractWithCustomerExcludingAssessedTax
Interest-bearing debtShort and long-term borrowings $4.5B 2026-09-30 LongTermDebtNoncurrent, LongTermDebtCurrent
Cash and interest-bearing securitiesCash, equivalents and marketable securities $6.3B 2026-09-30 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents, MarketableSecuritiesCurrent
Total assetsBalance sheet total $32.7B 2026-09-30 Assets
Market capDenominator for AAOIFI $141.7B live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $116.3B 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $117.6B 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $490.9M 2025-12-31 InvestmentIncomeInterestAndDividend

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet: Quarterly report (10-Q) filed 2026-11-03, period ended 2026-09-30. Income statement: Annual report (10-K) filed 2026-02-13, period ended 2025-12-31. Screened 2026-11-19.

  • Total assets$32.7B
    Assets · period ended 2026-09-30 · 10-Q filed 2026-11-03
  • Interest-bearing debt$4.5B
    LongTermDebtNoncurrent $3.5B · period ended 2026-09-30 · 10-Q filed 2026-11-03
    LongTermDebtCurrent $999.6M · period ended 2026-09-30 · 10-Q filed 2026-11-03
  • Cash and interest-bearing securities$6.3B
    CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents $5.0B · period ended 2026-09-30 · 10-Q filed 2026-11-03
    MarketableSecuritiesCurrent $1.3B · period ended 2026-09-30 · 10-Q filed 2026-11-03
  • Receivables$2.3B
    AccountsReceivableNetCurrent · period ended 2026-09-30 · 10-Q filed 2026-11-03
  • Revenue$12.0B
    RevenueFromContractWithCustomerExcludingAssessedTax · period ended 2025-12-31 · 10-K filed 2026-02-13
  • Interest income (non-permissible)$490.9M
    InvestmentIncomeInterestAndDividend · period ended 2025-12-31 · 10-K filed 2026-02-13
  • Market cap$141.7B
    Market quote passed in by the screen (Finnhub company profile; Yahoo Finance where Finnhub has none), 2026-11-19 · not a filing figure, so no link

8 reported values cited from 2 SEC filings, read from SEC's XBRL company facts when this symbol was screened. A link opens the filing's index on EDGAR.

What changed, and when

Verdict history for VRTX. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-11-19 Fail → Pass filing re-screen
  • 2026-11-19 Unverified → Pass filing re-screen

Tracked since 2026-09-07.

Revenue by business segment

How VRTX’s $12.0B of revenue for the fiscal year 2025-01-01 to 2025-12-31 splits across what it sells, as the company tags it in its own 10-K.

Fiscal year ended 2025-12-31
SegmentShareRevenue
TRIKAFTA/KAFTRIO 85.9% $10.3B
ALYFTREK 7.0% $837.8M
Other product revenues 6.8% $820.1M
Other revenues 0.3% $30.7M

These are the company’s own segment names and figures. They do not say whether a line of business is permissible; our business-activity screen does.

Source: 10-K filed 2026-02-13 (accession 0000875320-26-000056), read from its XBRL on SEC EDGAR. Shares are of total revenue; subtotals and overlapping cuts the filing also tags are left out, so the lines add up to the total.

What would change the status

The headline verdict is the majority of the decided ratio standards — 7 pass and 0 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-19.

Within 3 points of the line

AAOIFI, Dow Jones Islamic, FTSE Shariah, MSCI Islamic, MSCI Islamic M-Series, S&P Shariah, Usmani are within 3 points of their line. If they all crossed, the majority verdict would move from Compliant to Not compliant.

The ratios that move with the share price

AAOIFI's debt ratio (4.6% against a 30% line) would only fail if the market cap fell by 85%, to $21.6B. At the 2026-11-20 close it would read 4.7%.

AAOIFI's investments ratio (4.5% against a 30% line) would only fail if the market cap fell by 85%, to $21.0B. At the 2026-11-20 close it would read 4.5%.

Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.

Shariah-compliant alternatives

Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
REGNRegeneron Pharmaceuticals, Inc. $85.3B —
ARGXArgen X SE - ADR $64.3B —
ONCBeOne Medicines Ltd. American Depositary Shares $40.4B —
ALNYAlnylam Pharmaceuticals Inc $31.6B —
INCYIncyte Corp. $25.9B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Funds that hold VRTX

31 of the 238 funds whose filed holdings we currently hold own VRTX shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns VRTX.

Shariah funds
FundVRTX in fundFund compliant by weight
MNZL Manzil Russell Halal USA Broad Market ETF 0.42% 88%
SPUS SP Funds S&P 500 Sharia Industry Exclusions ETF 0.36% 79%
HLAL Wahed FTSE USA Shariah ETF 0.35% 72%
You may already own it

Widely held U.S. index funds. If you own one, you own VRTX through it. None of them is a Shariah fund; the last column is our look-through of each.

FundVRTX in fundFund compliant by weight
QQQ Invesco QQQ Trust, Series 1 0.55% 69%
VUG VANGUARD GROWTH INDEX FUND 0.36% 63%
RSP Invesco S&P 500 Equal Weight ETF 0.21% 44%
SPY 0.20% 56%
VOO VANGUARD 500 INDEX FUND 0.20% 56%
IVV iShares Core S&P 500 ETF 0.20% 56%
SPYM State Street(R) SPDR(R) Portfolio S&P 500(R) ETF 0.20% 56%
SCHB Schwab U.S. Broad Market ETF 0.19% 53%
VTI VANGUARD TOTAL STOCK MARKET INDEX FUND 0.17% 54%
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.17% 54%
Other funds
FundVRTX in fundFund compliant by weight
AGTHX Growth Fund of America 1.99% 54%
TNPFX New Perspective Fund 0.98% 57%
IYCEX Nomura Core Equity Fund 0.79% 53%
REVCX Columbia Global Value Fund Also REVRX 0.78% 40%
RYCOX NASDAQ-100 Fund 0.53% 67%
RGLHX American Funds Global Insight Fund 0.37% 52%
RFNBX American Funds Fundamental Investors Also RFNCX, RFNEX, RFNHX 0.32% 51%
TNRAX 1290 Avantis U.S. Large Cap Growth Fund Also TNXRX 0.32% 62%
PREFX T. Rowe Price Tax-Efficient Equity Fund 0.28% 62%
USCL iShares Climate Conscious & Transition MSCI USA ETF 0.25% 57%
8 more funds
FundVRTX in fundFund compliant by weight
PDSIX PGIM Quant Solutions Large-Cap Index Fund 0.20% 55%
OEICX JPMorgan Equity Index Fund 0.19% 55%
WFILX Allspring Index Fund 0.19% 55%
MSPIX NYLIM S&P 500 Index Fund 0.19% 53%
AVLC Avantis U.S. Large Cap Equity ETF 0.18% 51%
DFSU Dimensional US Sustainability Core 1 ETF 0.17% 49%
GSRTX Goldman Sachs Absolute Return Tracker Fund 0.07% not computed
REQAX Sustainable Equity Fund Also REQTX, REUYX 0.03% 55%

Sorted by VRTX’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names VRTX once, so a bond is not counted as the shares; 2 more funds name VRTX in a way we cannot separate from its bonds, and are not listed. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.

Tracked investors holding VRTX
InvestorFirmPositionWeightAs of
Ken Griffin Citadel Advisors $761M 0.1% 2026-09-30
Israel Englander Millennium Management $378M 0.1% 2026-09-30
Peter Brown Renaissance Technologies $207M 0.3% 2026-09-30
Baillie Gifford Baillie Gifford & Co $139M 0.1% 2026-09-30
Ray Dalio Bridgewater Associates $18M 0.1% 2026-09-30
Joel Greenblatt Gotham Asset Management $17M 0.0% 2026-09-30
Ken Fisher Fisher Asset Management $15M 0.0% 2026-09-30
Tweedy, Browne Tweedy, Browne Company $14M 1.1% 2026-09-30
Jefferies Jefferies Financial Group $8M 0.1% 2026-09-30
Paul Tudor Jones Tudor Investment Corp $5M 0.0% 2026-09-30
Ron Baron Baron Capital (BAMCO) $4M 0.0% 2026-09-30
Wahed Invest Wahed Invest LLC $3M 0.3% 2026-06-30
David Shaw D. E. Shaw & Co. $3M 0.0% 2026-09-30
Steven Cohen Point72 Asset Management $1M 0.0% 2026-09-30
Sallie Krawcheck Ellevest $1M 0.1% 2026-09-30
Mario Gabelli GAMCO Investors $0M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

558.88524.97491.06457.15423.242025-11-212026-05-262026-11-20

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
493.09
S2
505.45
S1
513.06
PIVOT
525.42
R1
533.03
R2
545.39
R3
553.00

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
493.93 – 558.45
±6.13% from 526.19, made 2026-09-28 · resolves 2026-10-05
STRONG BUY
from 19 indicators
78.6% of our last 30385 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 53.9% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsNEUTRAL
3 buy · 1 neutral · 3 sell
Moving averagesSTRONG SELL
3 buy · 0 neutral · 9 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)40.90NEUTRAL
Stochastic %K (14)2.53BUY
CCI (20)-134.91BUY
Williams %R (14)-97.47BUY
MACD (12,26,9)-3.83SELL
ROC (10)-5.86SELL
Momentum (10)-32.07SELL
EMA (10)532.24SELL
SMA (10)537.11SELL
EMA (20)532.96SELL
SMA (20)538.04SELL
EMA (30)530.86SELL
SMA (30)528.67SELL
EMA (50)526.17SELL
SMA (50)522.73SELL
EMA (100)513.57BUY
SMA (100)516.69SELL
EMA (200)490.13BUY
SMA (200)484.88BUY

About VRTX

Healthcare · Biotechnology

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

vrtx.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Latest Signal — 2026-11-20

MEAN REVERSION
Type
520.66
Entry
517.88
Stop
537.93
Target
LOSS
Outcome · exit 515.73 (-0.95%)

Stop 517.88 Now 516.05 Target 537.93

Verdict

🟡 BULLISH LEAN

The main driver: outperforming the market by 6.2%, RSI in healthy zone, Wall Street broadly bullish. More signals pointing up than down. Not full confluence yet, but the weight of evidence is bullish. Use `!alert VRTX [level]` to catch the entry, or `!plan VRTX` to size small.

Scores: 3 bullish / 2 bearish

Grade verdict

Good setup, solid confluence

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BEARISH 64
⏰ 4H BEARISH 43
🕐 1H BEARISH 98
⏱ 15-Min BEARISH 130
⏲ 5-Min BULLISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-3.6%
Rate of change (10d)
2.9×
Volume vs its 20-day average
1.85
MACD (no fresh cross)

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

CLUSTER SELL   0 buys · 4 sells

Recent: Tatsis Ourania sold 45321 sh @ $524.99 (2026-07-02); Liu Joy sold 19131 sh @ $502.71 (2026-07-01); Bozic Carmen sold 15933 sh @ $462.17 (2026-06-18)

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-17 · Asset managers net 895049 (-19081)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.